Moleculin shareholders approve reverse split authority up to 1-for-20; supermajority removal fails

Moleculin Biotech, Inc.

Shareholders approved board authority for a reverse stock split at a ratio of 1-for-2 to 1-for-20, exercisable before the one-year anniversary of the Oct. 9, 2026 annual meeting.
Amendment to eliminate supermajority charter-voting requirements failed, falling short of the required two-thirds of outstanding shares (2,828,497 for, 901,488 against).
Stockholders approved an amendment to the 2024 Stock Plan adding 3,861,894 shares; the 8-K states 3,875,999 shares total authorized for issuance.
Re-elected directors Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco and Elizabeth A. Cermak; Grant Thornton LLP ratified as auditor for fiscal 2026 and say-on-pay passed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.